Pain management

Summit Health Names Timothy Reish, M.D., Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry

Retrieved on: 
Tuesday, April 2, 2024
Health, Surgery, Practice Management, Physical Therapy, Other Health, Managed Care, General Health, Knee, Shoulder, Orthopedic surgery, Patient, Franklin Avenue, Research, Pain management, Elbow, Summit Health, Summit, Sports medicine, Dentistry

Timothy Reish, M.D., has been named Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry of Summit Health’s NY South region.

Key Points: 
  • Timothy Reish, M.D., has been named Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry of Summit Health’s NY South region.
  • He has been a practicing Orthopedic Surgeon in New York City for more than 20 years.
  • “We are thrilled that Dr. Reish will be leading three of our key departments that are essential to the health and well-being of our patients throughout their lifetime,” said Christine Masterson, M.D., executive vice president at Summit Health.
  • “I look forward to helping our Orthopedics, and Sports Medicine, Pain Management and Podiatry departments stay at the forefront of healthcare by offering the latest advancements and cutting-edge techniques in the fields of Orthopedics and Sports Medicine, Pain Management and Podiatry,” said Dr. Reish.

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
Tuesday, April 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

Garnett Station Partners Launches Accident Care Alliance, a Specialized Accident Injury Healthcare Services Platform

Retrieved on: 
Tuesday, April 2, 2024
Automotive, Physical Therapy, Professional Services, Managed Care, Other Health, Health, General Health, Neurology, Other Automotive, Asset Management, Telemedicine, Virtual Medicine, Pain management, Chiropractic, Patient, Garnett station, Accident, TBI, ACA, Elective surgery, Health insurance

Garnett Station Partners (“Garnett Station”), a New York-based principal investment firm that manages over $2.3 billion of assets, today announced the launch of Accident Care Alliance (“ACA”), a highly specialized platform comprised of best-in-class healthcare providers focused on delivering holistic, individualized care for those injured primarily in automobile accidents.

Key Points: 
  • Garnett Station Partners (“Garnett Station”), a New York-based principal investment firm that manages over $2.3 billion of assets, today announced the launch of Accident Care Alliance (“ACA”), a highly specialized platform comprised of best-in-class healthcare providers focused on delivering holistic, individualized care for those injured primarily in automobile accidents.
  • ACA partners with and grows industry-leading healthcare providers that support an underserved population of individuals injured in automobile accidents and are in need of adequate access to timely, premium healthcare services.
  • “We are building ACA around delivering convenient access and exceptional services to patients who lack access to best-in-class treatment options.
  • Rafi Haramati, Principal at Garnett Station, added, “The accident injury healthcare market is highly fragmented and growing, and with over half of accident injury cases in the United States resulting from automobile accidents, we see a great opportunity to build the leading platform to help improve the services available to injured patients.

Global Transdermal Medical Patch Market Analysis and Forecast to 2029: Growing Number of Smokers, Rising use for Insulin Delivery and Upswing in Hormonal Deficiencies Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Medical Supplies, Retail, Health, Tobacco, General Health, Pharmaceutical, Biotechnology, Hypersensitivity, Plasma, Obesity, Growth, Prevalence, Rheumatoid arthritis, Application, Incidence, Diabetes, Patient, Pharmacy, Conditional sentence, Chronic pain, Stroke, Hospital, Smoker, Cancer, Nature, Migraine, Distribution, Arthritis, Nausea, Diabetic neuropathy, Smoking, Skin, Pain management, Pain, Allergy, Market, Vomiting, Osteoarthritis, Ageing, Pharmaceutical industry

The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global transdermal medical patch market was valued at US$7.88 billion in 2023 and is expected to reach US$10.33 billion by 2029.
  • The global transdermal medical patch market is highly competitive in nature, characterized by fierce competition among industry leaders vying to expand their market presence.
  • The key players in the global transdermal medical patch market are:

Virpax Pharmaceuticals Reports 2023 Year-End Results

Retrieved on: 
Tuesday, March 26, 2024
Other Health, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Science, Surgery, Veterinary, Biotechnology, Practice Management, Other Science, Health, Research, NCATS, Development, Plaintiff, Post-traumatic stress disorder, Central nervous system, CNS, CRADA, Trauma, Bupivacaine, Chronic pain, NIH, IND, United States bankruptcy court, Bankruptcy, Therapy, FINANCIAL, Pain management, Bangladesh Technical Education Board, Pentagon, Government, Pharmaceutical industry

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments.
  • “Recently we reported the initial results from the pilot study of Probudur™ performed by the U.S. Army Institute of Surgical Research (USAISR).
  • On November 17, 2023, Virpax announced the resignation of Anthony P. Mack as CEO and Chairman effective immediately.
  • As of December 31, 2023, Virpax had cash of approximately $9.1 million, compared to $19.0 million as of December 31, 2022.

Small Door Opens First Maryland Practice With New Bethesda Location

Retrieved on: 
Monday, March 18, 2024
Other Consumer, Other Health, Retail, Pets, Other Professional Services, Telemedicine, Virtual Medicine, Urban Planning, Family, Consumer, Other Construction & Property, Professional Services, Department Stores, Practice Management, Veterinary, Commercial Building & Real Estate, Construction & Property, Other Retail, Health, AAHA, Internal medicine, American Animal Hospital Association, Dentistry, Entrepreneurship, Humane society, Partnership, Patient, Accreditation, Animal science, Madeira School, University, Veterinary medicine, Telehealth, Federal Realty Investment Trust, Wildwood, Public, Dermatology, Infection, B Corporation (certification), Pain management, Missouri College, Pet, CCRP, Rehabilitation

Small Door Inc., a tech-enabled, membership-based veterinary care provider that operates under the brand Small Door Veterinary , today opened its first location in Maryland and will now be accepting new members at its state-of-the-art practice in Bethesda (10253 Old Georgetown Rd).

Key Points: 
  • Small Door Inc., a tech-enabled, membership-based veterinary care provider that operates under the brand Small Door Veterinary , today opened its first location in Maryland and will now be accepting new members at its state-of-the-art practice in Bethesda (10253 Old Georgetown Rd).
  • The new facility, located in the Wildwood Shopping Center, is the fourth location to open in the DMV (District of Columbia, Maryland, and Virginia), as Small Door continues to address a growing need for veterinary medicine amongst local pet owners.
  • The opening marks the eleventh Small Door location overall, continuing a steady expansion plan.
  • Launching at Wildwood Shopping Center continues our strategic rollout across the Greater Washington market,” explained Josh Guttman, Co-Founder and CEO of Small Door.

Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Venture Capital, Manufacturing, Finance, Pharmaceutical, Professional Services, Oncology, Practice Management, Mental Health, Research, Science, Other Manufacturing, COVID-19, CDMO, Patient, Psychological abuse, NIH, Clinical trial, Ground substance, National Institutes of Health, API, NCE, Pain management, Bangladesh Technical Education Board, Multimedia, Government, New chemical entity, Fine chemical

This strategic combination unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.

Key Points: 
  • This strategic combination unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.
  • View the full release here: https://www.businesswire.com/news/home/20240314509251/en/
    The strategic combination of Noramco, Purisys, and Halo Pharma unites the strengths of these entities to provide a robust, North American-based supply chain solution for both clinical and commercial APIs and drug products.
  • Lee Karras, CEO of the Noramco Group, emphasized the importance of this alignment in the current market, stating, "The COVID-19 pandemic exposed critical vulnerabilities in our drug supply chain.
  • To explore how the Noramco Group can support API to drug product supply needs, visit www.noramco.com .

Regional Medical Associates Achieves Up to 90% Time Savings on Clinical Documentation with Sunoh.ai and eClinicalWorks EHR

Retrieved on: 
Wednesday, March 13, 2024
Apps, Applications, Technology, Health Technology, Software, Networks, Practice Management, General Health, Health, Data Management, Artificial Intelligence, Documentation, Patient, Acupuncture, Android, Chronic pain, Pain management, EHR, IOS, Physician, Medical device

eClinicalWorks® , the largest ambulatory cloud EHR and first AI-driven EHR, today announced that Regional Medical Associates has successfully implemented medical AI scribe, Sunoh.ai, saving significant time on clinical documentation.

Key Points: 
  • eClinicalWorks® , the largest ambulatory cloud EHR and first AI-driven EHR, today announced that Regional Medical Associates has successfully implemented medical AI scribe, Sunoh.ai, saving significant time on clinical documentation.
  • As a result of the eClinicalWorks integration with Sunoh.ai , the medical AI scribe is easily available to eClinicalWorks customers, including Regional Medical Associates.
  • Regional Medical Associates sought a medical AI scribe solution to save physicians time documenting patient information, enhancing efficiency in clinical documentation by reducing errors and streamlining workflows.
  • “Sunoh.ai understands my accent and provides close to 90% or more accuracy in transcribing clinical documentation,” said Dr. Ganesh Balu, physiatrist and pain management specialist at Regional Medical Associates.

Nura Pain Clinics Welcomes Dr. Larry Studt as Patient Care Capabilities and Demand Continue to Grow

Retrieved on: 
Wednesday, April 3, 2024
Family, Patient, Chronic pain, Minneapolis–Saint Paul, Pain management, Pain, Physician, Occupational medicine, Singing, Nursing

EDINA, Minn., April 3, 2024 /PRNewswire/ -- Nura Pain Clinics, Minnesota's foremost multidisciplinary pain management clinic, announced today that Dr. Larry Studt will join their team of pain management providers this month.  

Key Points: 
  • EDINA, Minn., April 3, 2024 /PRNewswire/ -- Nura Pain Clinics , Minnesota's foremost multidisciplinary pain management clinic, announced today that Dr. Larry Studt will join their team of pain management providers this month.
  • Nura, a subsidiary of the Capitol Pain family of practices, is committed to delivering exceptional patient-centered care, especially as demands for their pain services continue to grow.
  • With the addition of Dr. Studt, Nura now has two full-time providers dedicated to seeing new patients.
  • For more information on Nura Pain Clinics and its focus on pain management, visit nuraclinics.com .

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Retrieved on: 
Tuesday, April 2, 2024
Perioperative medicine, Database, Pain, Patient, Anesthesiology, City, News, Pain management, General surgery, Fever, Safety, NSAID

NASHVILLE, Tenn., April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants.

Key Points: 
  • As part of a comprehensive safety and efficacy developmental plan, IVIB was studied in various treatment areas, including surgical pain, fever and nonsurgical acute pain.
  • IVIB is the only non-opioid injectable analgesic approved for use in children as young as 3 months of age.
  • "Pain management has become one of the most common health care problems," said A.J.
  • "As this new report states, comprehensive multimodal pain regimens have become key in preventing pain and optimizing pain control, while minimizing the need for opioids.